search
Back to results

LIFEwithIBD: Living With Intention, Fullness and Engagement With Inflammatory Bowel Disease (LIFEwithIBD)

Primary Purpose

Inflammatory Bowel Diseases

Status
Completed
Phase
Not Applicable
Locations
Portugal
Study Type
Interventional
Intervention
LIFEwithIBD
Sponsored by
University of Coimbra
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Inflammatory Bowel Diseases

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • diagnosis of IBD for more than 6 months (CD or UC)

Exclusion Criteria:

  • having started new treatment for IBD in the previous 6 months (in the case of anti-TNF and immunosuppressive therapy) or 2 months (in the case of steroid or aminosalicylate therapy)
  • cognitive impairment;
  • currently undergoing any form of psychological intervention;
  • current diagnosis of severe psychiatric illness (severe depression, psychotic illness, bipolar disorder, substance abuse) or suicidal ideation;
  • diagnosis of other serious health condition;
  • pregnancy.

Sites / Locations

  • Centro Hospitalar e Universitário de Coimbra

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

No Intervention

Arm Label

Experimental group

Control group

Arm Description

LIFEwithIBD Programme is a manualized acceptance, mindfulness and compassionate-based group intervention for inflammatory bowel disease patients. It included 9 weekly group sessions, 1.30h hours each, run in small groups (ranging from 10 to 15 participants). Participants in this group also receive inflammatory bowel disease treatment as usually performed at the Coimbra University Hospital.

Treatment as Usual (TAU) Standard personalized treatment of inflammatory bowel disease

Outcomes

Primary Outcome Measures

Indicators of psychopathology (DASS-21)
Indicators of psychopathology, namely depression, anxiety and stress symptoms will be measured by Depression, Anxiety and Stress Scale-21. DASS-21 assesses levels of depression, anxiety, and stress symptoms. Respondents are asked to indicate how frequently they experienced such symptoms over the previous week on a 4-point scale (ranging from 0 = "Did not apply to me at all" to 3 = "Applied to me very much, or most of the time"). Results of each subscale are calculated by the sum of the results of the seven items. The scale provides three notes, one per subscale, where the minimum is "0" and the maximum is "21". Higher results correspond to more negative affective states.

Secondary Outcome Measures

Perception of Quality of Life (World Health Organization Brief Quality of Life Assessment Scale)
Quality of life will be measure by World Health Organization Brief Quality of Life Assessment Scale.The WHOQOL-BREF is a 24-item measure of subjective perceptions of QoL. Items are rated on a 5-point Likert scale (higher scores indicate perceptions of higher QoL) and are distributed over four domains-physical health (e.g. "To what extent do you feel that physical pain prevents you from doing what you need to do?"), psychological health (e.g. "How often do you have negative feelings such as blue mood, despair, anxiety, depression?"-reverse item),social relationships (e.g. "How satisfied are you with your personal relationships?"), and environment. The scale also presents two additional items that evaluate general quality of life and general health.
Biochemical indicator: concentration levels of calprotectin
This biochemical indicator will be measured though concentration levels of calprotectin in unit of measure of miligram/liter (mg/L)
Biochemical indicator: concentration levels of C-reactive protein (CRP)
This biochemical indicator will be measured though concentration levels of C-reactive protein (CRP) in unit of measure of microgram/gram (µg/g)

Full Information

First Posted
February 5, 2019
Last Updated
November 5, 2021
Sponsor
University of Coimbra
Collaborators
Centro Hospitalar e Universitário de Coimbra, E.P.E.
search

1. Study Identification

Unique Protocol Identification Number
NCT03840707
Brief Title
LIFEwithIBD: Living With Intention, Fullness and Engagement With Inflammatory Bowel Disease
Acronym
LIFEwithIBD
Official Title
LIFEwithIBD: Living With Intention, Fullness and Engagement With Inflammatory Bowel Disease: The Impact of a Group Intervention and an ICT-based Transcultural Intervention on Physical and Mental Health
Study Type
Interventional

2. Study Status

Record Verification Date
November 2021
Overall Recruitment Status
Completed
Study Start Date
May 27, 2019 (Actual)
Primary Completion Date
February 28, 2021 (Actual)
Study Completion Date
February 28, 2021 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Coimbra
Collaborators
Centro Hospitalar e Universitário de Coimbra, E.P.E.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This investigation aims to apply and test the feasibility of an acceptance, mindfulness and compassionate-based intervention structured for inflammatory bowel disease patients. LIFEwithIBD programme for inflammatory bowel disease thus comprises 9 weekly group sessions, lasting 1 and a half hour each, run in small groups at a Gastroenterology Service at the Coimbra's University Hospital. For each week participants have assigned homework (e.g., mindfulness exercises). The efficacy of LIFE-IBD Group Intervention to improve quality of life, mental health, and disease activity-related scores will be tested in a sample of Portuguese patients. Additionally, this study expected that the observable changes after the intervention completion will be attributed to changes in emotional regulation processes and maintained over the follow-up periods.
Detailed Description
The sample will include diagnosed inflammatory bowel disease patients recruited at a Gastroenterology Service at the Coimbra's University Hospital, a national reference centre for IBD. Patients will be approached by their doctor to assess their level of interest in the investigation. Patients who demonstrate interest will go through a Screening interview conducted by a psychologist that aims explain the structure and arms of the investigation, to collect demographic data, and whether the patient meets the inclusion criteria for the study. After sample collection, participants will be randomly assigned to one of two conditions: experimental group (n=75) or control group (n=75). The experimental group will be divided into five subgroups of 15 participants. The first group will function as a pilot group to test the suitability of the programme. The intervention will include 8 weekly sessions, with the duration of 90 minutes each. Groups will have two therapists with experience in ACT and CFT-based interventions. All participants will continue on receiving the recommended pharmacological treatment for IBD (TAU). This will allow the comparison between the participants receiving the LIFE-IBD Group Intervention+TAU (experimental group) and the participants only receiving TAU (control group). The frequency of engagement with the programme at home practises will be analysed as moderator of the efficacy of the programme. Both groups will concurrently complete a protocol of measures to assess main three areas: a) psychological processes; b) quality of life and psychopathology; c) current medical status. These assessments will occur in four different times: before the start of the LIFEwithIBD programme M0), after the final session of the programme (M1), and 3 (M2) and 6 months (M4) after that.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Inflammatory Bowel Diseases

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
76 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Experimental group
Arm Type
Experimental
Arm Description
LIFEwithIBD Programme is a manualized acceptance, mindfulness and compassionate-based group intervention for inflammatory bowel disease patients. It included 9 weekly group sessions, 1.30h hours each, run in small groups (ranging from 10 to 15 participants). Participants in this group also receive inflammatory bowel disease treatment as usually performed at the Coimbra University Hospital.
Arm Title
Control group
Arm Type
No Intervention
Arm Description
Treatment as Usual (TAU) Standard personalized treatment of inflammatory bowel disease
Intervention Type
Behavioral
Intervention Name(s)
LIFEwithIBD
Intervention Description
LIFEwithIBD programme is a psychotherapeutic programme based on Acceptance, Mindfulness and Compassion for inflammatory bowel disease patients Treatment as Usual (TAU): Standard personalized treatment of inflammatory bowel disease
Primary Outcome Measure Information:
Title
Indicators of psychopathology (DASS-21)
Description
Indicators of psychopathology, namely depression, anxiety and stress symptoms will be measured by Depression, Anxiety and Stress Scale-21. DASS-21 assesses levels of depression, anxiety, and stress symptoms. Respondents are asked to indicate how frequently they experienced such symptoms over the previous week on a 4-point scale (ranging from 0 = "Did not apply to me at all" to 3 = "Applied to me very much, or most of the time"). Results of each subscale are calculated by the sum of the results of the seven items. The scale provides three notes, one per subscale, where the minimum is "0" and the maximum is "21". Higher results correspond to more negative affective states.
Time Frame
From Baseline to 3-months follow-up
Secondary Outcome Measure Information:
Title
Perception of Quality of Life (World Health Organization Brief Quality of Life Assessment Scale)
Description
Quality of life will be measure by World Health Organization Brief Quality of Life Assessment Scale.The WHOQOL-BREF is a 24-item measure of subjective perceptions of QoL. Items are rated on a 5-point Likert scale (higher scores indicate perceptions of higher QoL) and are distributed over four domains-physical health (e.g. "To what extent do you feel that physical pain prevents you from doing what you need to do?"), psychological health (e.g. "How often do you have negative feelings such as blue mood, despair, anxiety, depression?"-reverse item),social relationships (e.g. "How satisfied are you with your personal relationships?"), and environment. The scale also presents two additional items that evaluate general quality of life and general health.
Time Frame
From Baseline to 3-months follow-up
Title
Biochemical indicator: concentration levels of calprotectin
Description
This biochemical indicator will be measured though concentration levels of calprotectin in unit of measure of miligram/liter (mg/L)
Time Frame
From Baseline to 3-months follow-up
Title
Biochemical indicator: concentration levels of C-reactive protein (CRP)
Description
This biochemical indicator will be measured though concentration levels of C-reactive protein (CRP) in unit of measure of microgram/gram (µg/g)
Time Frame
From Baseline to 3-months follow-up

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: diagnosis of IBD for more than 6 months (CD or UC) Exclusion Criteria: having started new treatment for IBD in the previous 6 months (in the case of anti-TNF and immunosuppressive therapy) or 2 months (in the case of steroid or aminosalicylate therapy) cognitive impairment; currently undergoing any form of psychological intervention; current diagnosis of severe psychiatric illness (severe depression, psychotic illness, bipolar disorder, substance abuse) or suicidal ideation; diagnosis of other serious health condition; pregnancy.
Facility Information:
Facility Name
Centro Hospitalar e Universitário de Coimbra
City
Coimbra
Country
Portugal

12. IPD Sharing Statement

Citations:
PubMed Identifier
34489756
Citation
Trindade IA, Pereira J, Galhardo A, Ferreira NB, Lucena-Santos P, Carvalho SA, Oliveira S, Skvarc D, Rocha BS, Portela F, Ferreira C. The LIFEwithIBD Intervention: Study Protocol for a Randomized Controlled Trial of a Face-to-Face Acceptance and Commitment Therapy and Compassion-Based Intervention Tailored to People With Inflammatory Bowel Disease. Front Psychiatry. 2021 Aug 19;12:699367. doi: 10.3389/fpsyt.2021.699367. eCollection 2021. Erratum In: Front Psychiatry. 2022 Feb 14;13:837357. Front Psychiatry. 2022 Jul 05;13:969795.
Results Reference
derived

Learn more about this trial

LIFEwithIBD: Living With Intention, Fullness and Engagement With Inflammatory Bowel Disease

We'll reach out to this number within 24 hrs